TicoVac 1.2 ug/.25mL

Tick-borne encephalitis vaccine, the active ingredient in TicoVac 1.2 µg/0.25 mL, is a viral vaccine presented as a 1.2 µg/0.25 mL injection for intramuscular use. It is indicated for the prevention of tick-borne encephalitis (TBE) in individuals aged 1 year and older.

GNH USA supplies TicoVac 1.2 µg/0.25 mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

TicoVac 1.2 µg/0.25 mL is a vaccine designed to prevent tick-borne encephalitis (TBE), a viral infection transmitted by ticks.

- Tick-borne encephalitis: Prevents TBE in individuals aged 1 year and older. - Active immunization: Provides protection against TBE virus through the stimulation of the immune system.

TicoVac 1.2 µg/0.25 mL may cause side effects, although not everyone gets them.

Common Side Effects: - Local tenderness - Local pain - Fatigue - Headache - Muscle pain - Fever - Restlessness

Serious or Rare Side Effects: - Severe allergic reactions - Weakened immune response in individuals with compromised immune systems

TicoVac 1.2 µg/0.25 mL should be used with caution and under the supervision of a healthcare provider.

- Allergic reactions: Avoid if you have a history of severe allergic reactions to previous doses of TicoVac. - Pregnancy: Inform your healthcare provider if you are pregnant or plan to become pregnant. - Weakened immune systems: Individuals with weakened immune systems may have a reduced immune response. - Protection: TicoVac may not protect all individuals against TBE. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

TicoVac 1.2 µg/0.25 mL may interact with other medications or substances.

Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - Immunosuppressants: May reduce the effectiveness of the vaccine. - Other vaccines: Consult your healthcare provider before receiving other vaccines simultaneously.